F2RL1 and osteoarthritis: To further investigate how PAR-2 can be a potential therapeutic target of osteoarthritis (OA), we designed a PAR-2-inhibiting peptide (PAR2-IP) by replacing an isoleucine residue in the PAR2-AP with alanine, generating the SLAGKV peptide.